Journal of Population Therapeutics & Clinical Pharmacology

REVIEW ARTICLE
DOI: 10.53555/jptcp.v30i17.2783

PHARMACOECONOMICS BURDEN OF ADVERSE DRUG REACTION; A SCOPING REVIEW ARTICLE

Priya Nagar*[1], Anjali Kumari[1], Deepanshu Kumar[1], Piyush Mittal[1]
[1]Teerthanker Mahaveer College of pharmacy, Teerthanker Mahaveer university, Moradabad/244001, India.

***Corresponding Author:** - Priya Nagar* Priyanagr764@gmail.com

Coauthor:- anjaliim1414@gmail.com, Dkdeepanshu.890@gmail.com, Piyush.pharmacy@tmu.ac.in.

Abstract
Adverse drug reactions (ADRs) are frequently underreported. Adverse drug reactions (ADRs) are a severe health hazard that leads to avoidable patient burden and hospital admissions; hence pharmacovigilance education is critical. Only a few educational initiatives have long-term benefits on healthcare personnel' understanding of pharmacovigilance and adverse event reporting. Our healthcare practitioners of the future should develop a sufficient set of pharmacovigilance skills in order to rationally prescribe, distribute, and monitor medications. This study is being carried out to irrational use of medications of various classes in surgery department which can cause unexpected and life- threating adverse drug reactions and noxious events. Due to that adverse drug reaction or noxious events the stay of the patient in hospital gets prolonged which can make him/her suffer the unexpected financial burden.

Keywords: Pharmacoeconomics, Adverse Drug reaction, Adverse events, Surgery ADRs

Introduction
An adverse drug reaction (ADR) is expressed by the WHO as "A response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modifications of physiological function." ADR is a prime origin of illness and death around the world. They're associated with higher healthcare costs as a result of hospitalizations or lengthier stays, as well as more interventions.[1]

The detection of ADRs in hospitals allows for the detection of major ADRs that results in hospitalization as well as ADR that occurs in hospitalized patients, i.e., patients with high comorbidity who are getting medications that are not approved by the FDA. As a consequence of the various ADR detection methods utilized, different rates and types of ADR occur, and as a result, distinct drug classes are accountable for these ADR.[2]

Adverse drug reactions have long been upraising a serious community health related problem. The number of ADRs turned to be reported. The percentage ranges from 3.7 percent to 30 percent.

ADR cost analysis involves critical questions, such as which perspective to use when studying ADR. In pharmacoeconomic, a social approach is recommended since it encompasses all pertinent information costs. Hospital expenditures, in particular, are included in the cost of ADR. Those that arise as a result of an increase in the duration of an ADR have prompted you to remain. Excessive costs are usually expensive. The number of days spent in the hospital is utilized to compute the additional cost.[3]

In terms of the resources required to handle ADR, health care systems around the world face a considerable burden. ADR have both direct and indirect expenses. ADR cost analysis involves critical questions, such as which perspective to use when studying ADR. In a pharmacoeconomic evaluation, a social approach is chosen because it considers all relevant factors. Hospital costs, particularly those resulting from a prolonged stay in hospital, are included in the cost of ADR. Typically, the cost of a prolonged stay in the hospital is to be utilized the determine the additional costs.[4]

Based on a study a sum of 5,118 children out of 6,601 admissions was covered in the study, with 17.7 percent experiencing minimal one ADR. More than half of all medicines implicated in ADR were opioids, pain reliever, and pharmaceutical product used in general anesthesia. 0.9 percent of these ADRs resulted in lasting damage or needed intensive care. Children who had general anesthesia are more prone to be likely to develop an ADR than children who did not have GA. 95% confidence interval (CI). Other risk variables for ADR were growing age, increased drug use, and oncological therapy.[5]

Another research found that during the 6-month trial period, 3565 admitted patients in general surgery wards reported 45 suspected Adverse Drug Reactions reported forms, with an overall frequency of 1.26 percent. The gastrointestinal system was the most usually implicated (51.7 percent). Antimicrobials were the most often associated drug class (80.2 percent). In terms of causation, 95.6 percent of ADRs were rated as "Possible," whereas 91.2 percent were classed as "light" in terms of severity. The majority of patients (66.7 percent) retrieved via ADR. ADR was increased and Type A in 73.3 percent of cases.[6]

Pharmacoeconomics is expressed as the explanation and study of drug therapy value to the health wellness programs and the community it defines, assesses, with contrast the costs and effects of pharmaceutical product and assistance.[7] Value is computed to evaluate the resources (or inputs) utilized in for the creation of a result. Costs are classified into four groups in pharmacoeconomic research.[8]

The importance of pharmacovigilance in ADR identification is underlined by the fact that improper medication usage is a primary cause of ADR. However, medications are used in RCTs according to stringent procedures, typically in patients who are not fragile, and in a highly controlled setting considerably different from the drug usage witnessed in dynamic clinical contexts in which the manner and effects of medication administration are studied drug use might be more complicated.[9]

The fundamental challenge with ADR in health care is determining whether and how to decrease ADR expenditures. To make an informed choice, both costs and advantages must be considered. ADR have two major costs: the expense of treating diseases caused by ADRs and the value of prevention. There are two expenses as interconnected as well as increasing cost of preventing ADR. As a result, the cost of treating ill or diseases will most likely be decreased with relation to ADR. The primary concern for health-care decision-taking is to strike proper stability between value on welfare of pharmacological therapy.[10]

When new antibiotics and other medications are introduced to the market, the situation worsens. Furthermore, for novel medicines in surgical treatment, a proactive strategy to ADR reporting is becoming increasingly crucial.[11] Approximately 22% of reported adverse medication responses have a higher impact on people's daily lives and need extra therapy, which may raise the risk.[12]

The reason for this study to assess ADR in surgery department due to which the stay of patients prolonged which cause the pharmacoeconomics burden on patients' family. As a result, it will assess Adverse Drug Reactions and pharmacoeconomic burden in the surgical department.

ADVERSE DRUG REACTIONS

Medication-related adverse events, often known as adverse drug reactions (ADRs), are dangerous side effects produced by medications. The World Health Organisation (WHO) defines adverse drug reactions (ADRs) as "a response to a medication that is noxious and unintendedly used in manman to treat." [13]

ADRs have the potential to have a significant impact on patients' quality of life while also increasing the cost to the healthcare system. ADRs are one of the leading causes of morbidity and death worldwide, and they will continue to be a serious public health concern as medication becomes more sophisticated to treat numerous diseases in an ageing population. According to a recent study, ADRs accounted for about 3.5% of hospital admissions.[14]

PREVALENCE (GLOBAL, NATIONAL)

According to this report, the total cases of ADRs was 12.4 percent, with ADRs triggering admitted accounting for 8.1 percent. Gastrointestinal ADRs were the most prevalent. Cardiovascular medications were the most prevalent cause of ADRs. Patients with ADRs stayed longer who did come up with any ADR). ADRs admitted which were caused by less than 3 drugs having a remote comment in Pharmacogenomics Knowledge base database (PharmGKB), implying pharmacogenetic testing might have anticipated some of these ADRs.[15]

Another study stated that around 309 individuals examined, 62.8 percent had at least one ADR, and 29.8 percent had severe responses, with a comparable men and women ratio. The major prevalent Adverse drug reaction was gastrointestinal symptoms, which were largely related with Atripla, followed by AZT + 3TC + NVP medication, whereas Berardinelli- seip syndrome was related to peripheral neuropathy, which was usually linked with Stavudine, and anemia, which was related with the most dangerous was zidovudine. ADR was more prevalent in patients with a CD4 level of less than 200.[16]

TYPES OF ADR

ADRs have traditionally been divided into two types:

1 Type A reactions- also known as enhanced reactions, are 'dose-dependent' and predicted based on the pharmacology of the medication.

2 Type B reactions - strange reactions - that are distinctive and unpredictable based on pharmacology.



Fig. 1 Classification of Adverse Drug Reactions [17]

Although this basic classification is still widely used, it does not apply to all ADRs, such as chronic adverse effects associated with cumulative drug exposure (eg, osteoporosis with long-term corticosteroid treatment) or withdrawal reactions (eg, rebound hypertension with centrally acting antihypertensive discontinuation). The 'DoTS' classification scheme is a second and maybe more thorough classification scheme that classifies responses based on the Dot se of the drug, the TIME course of the reaction, and pertinent susceptibility characteristics (such as genetic, pathological, and other biological variations).[17]

FACTORS AFFECTING

The dosage of medicine, frequency of administration, and time of day at which the drug is delivered all have a substantial impact on the occurrence of ADRs. ADRs may occur as a result of polypharmacy due to medication additive effects, synergism, duplication, drug interactions, therapy cessation, and physiological antagonism. Age has a substantial impact on the development of ADRs, notably in children and the elderly. Men have greater body weight, internal organ size, and glomerular filtration but less body fat than women; these differences impact both medication pharmacokinetics and pharmacodynamics. Because of its delicate nature, the foetus is vulnerable to medicine in the maternal circulation, and its limited metabolism and excretion ability might result in teratogenicity. The presence of various medical problems at the same time predisposes the patient to drug-disease interaction, which may finally lead to ADRs. For example, a rise in the incidence of idiosyncratic toxicity with anti-infective medicines such as trimethoprim-sulfamethoxazole. Genetic variables, which are responsible for genetic polymorphisms and individual variances in enzyme ability to metabolise medicine, as well as differences in drug receptors and transporters, are considered responsible for the ethnic background. Because of genetic variances, the occurrence of ADRs varies from one patient population to the next. [18]

SCALE FOR ASSESSMENT

To characterize ADRs, researchers devised a variety of causality evaluation methods based on various criteria such as comparable scales, theorems, probability scales, algorithms, and so on. However, because no standardized diagnostic criteria or classifications exist, inter-rater and intra-rater variability is high.[19]

Question	Yes	No	Don't know
Are there previous conclusion reports on this reaction ?	+1	0	0
Did the adverse event appear after the suspect drug was administered ?	+2	-1	0
Did the AR improve when the drug was discontinued or a specific antagonist was administered?	+1	0	0
Did the AR reappear when drug was re-administered?	+2	-1	0
Are there alternate cause [either the the drug] that could solely have caused the reaction?	-1	+2	0
Did the reaction reappear when a placebo was given ?	-1	+1	0
Was the drug detected in the blood[or other fluids]in a concentration known to be toxic?	+1	0	0
Was the reaction more severe when the dose was increased or less severe when the dose was decreased	+1	0	0
Did the patient have a similar reaction to the same or similar drug in any previous exposure?	+1	0	0
Was the adverse event confirmed by objective evidence?	+1	0	0

Table 1. Naranjo Algorithm [20]

Scoring for Naranjo algorithm;.9=definite ADR;5-8-probableADR;1-4=possible ADR;0-doubtfulADR

The most commonly used algorithm; the Naranjo algorithm (Table 1) is shown above. The Naranjo Algorithm is a questionnaire developed by Naranjo et al to assess the chance that an ADR (adverse drug reaction) is caused by the drug rather than by other variables. Probability is expressed as a score that might be certain, likely, possible, or questionable. Values derived from the method are occasionally used in peer reviews to validate the author's findings about adverse medication responses. It is also known as the Naranjo Scale or the Naranjo Score.[21]

IMPORTANCE OF STUDYING ADRs

The primary goal is to assess health care providers' knowledge and concerns regarding adverse medication reactions and the reporting of such claims. The creation and adoption of a system that includes adverse medication reaction reporting and health education experts in the detection, assessment, and controlling of adverse drug reactions.[22]

69.4 percent hospital ADRs were probably avoidable, according to the Schumock and Thornton algorithm, 24.2 percent were unavoidable, and 6.4 percent were inevitable must be unquestionably avoidable. The gastrointestinal tract and metabolism group, which includes mostly antidiabetics, was followed by "B" blood and blood products and "C" cardiovascular system, with the majority of patients receiving heart medicine and RAS inhibitors. Antimicrobials were another pharmaceutical category, with 50.0 percent utilization in the systemic and nervous systems, respectively. Unpreventable ADRs were connected to a much higher percentage of adverse reactions that occurred during hospitalization.[23]

MANAGEMENT OF ADR

The American Society of Health-System Pharmacists (ASHP) makes recommendations with emphasizes the role of pharmacists in ADR therapy. Here are some pointers:

- Recognize the patient's perspective on pharmaceutical therapy.
- Educate people on the advantages of therapy.
- Inform patients about potential ADRs and how to treat them if they arise.
- Maintain an up-to-date and accurate medication list.
- To assist prevent ADRs, we use decision support software.
- Begin with modest dosages and frequencies and gradually increase as tolerated.
- Begin with less powerful drugs, agents with direct modes of action, or alternatives with a reduced frequency of side events.
- Interacting drugs should be avoided or used in moderation.
- Prescribe dose formulations that have a low systemic exposure (e.g., creams, patches).[24]

Individual case data is particularly important, not in terms of numbers, but in terms of establishing with a high degree of certainty that a certain unfavorable pharmacological effect may occur at least once.

- Ensure an Extensive Medical History
- Specific Drug Adverse Effect Tests
- Drug and Dose Manipulation
- Interactions
- Genotyping
- Desensitization and rechallenge
- Adverse Drug Reaction Treatment [25]

The treatment of an adverse medication response includes reversing the immediate symptoms of anaphylaxis, identifying and eliminating the offending allergen, and developing a long-term prophylactic regimen. The early detection and treatment of anaphylaxis is critical in the management of adverse medication responses. This potentially fatal response has an explosive start and is the most common emergent allergic disaster symptoms may differ from little itchiness to severe hypotension and or catastrophic pulmonary insufficiency caused by laryngeal enema. These clinical symptoms are the result of two alterations in vascular and smooth muscle caused by the release of chemical mediators with biological activity originating from the mast cell. The prevention of adverse medication reactions constitutes optimal management, which is becoming increasingly difficult to achieve due to the frequent multiplicity of adverse drug reactions typical currently prescribed medication regimens.[26]

PHARMACOECONOMICS

Pharmacoeconomics is a branch discipline of economics that examines the value of several pharmacological treatments and therapeutic therapies. It's a subset of the field of health economics. The cost and effectiveness of a pharmaceutical product are evaluated in a pharmacoeconomic research. Pharmacoeconomic studies aid in the allocation of healthcare resources in a consistent and scientifically sound manner.[27]

Pharmacoeconomic approaches aid in the verification of the value of the drug and the advantages of numerous treatment plans and services, thus might aid in the establishment of importance for those alternatives and the allocation of suitable resources in ever-changing healthcare landscapes.[28]

ECONOMIC EVALUATION FINDING

- Cost-minimization analysis (CMA): determining which alternative therapies are the least expensive and yield similar results in terms of health
- Cost-effectiveness analysis (CEA): it compares the treatments in terms of costs and results in monetary units reflected in nonmonetary quantitative health measures, death or incidence are lower, for example.

- Cost-utility analysis (CUA): a type of CEA in which monetary costs are weighed against health outcomes. As assessed by quality-adjusted life years, utility, and mortality. QALY is a wide outcome statistic with into account improvements in morbidity and death.
- Cost-consequence analysis (CCA): In this sort of CEA, costs and health outcomes are reported in distinct categories with no aggregate or weighting.
- Cost-benefit analysis (CBA): Costs, health benefits (and hazards), and financial units are all measured.[29]

IMPORTANCE OF PHARMACOECONOMICS

Pharmacoeconomics is a critical for drug producers in explaining the value of their goods to external decision-makers (payers, prescribers, and patients), as well as obtaining regulatory and reimbursement clearances assisting in commercial success. Because the discovery of new pharmaceuticals are time-consuming, expensive, and dangerous, because considerable research and development (R&D) resources must be allocated, pharmacoeconomics plays a critical role in influencing internal decision-making (inside a company) during pharmaceutical development.[30]

As a result, it is easy to understand how the costliest medication product among a group of other pharmaceuticals in the same therapeutic area may end up being the most expensive and be the least expensive medicine to use on a global scale. Here's where Pharmacoeconomics makes an important contribution.[31]

Societal and cultural values have a significant role in selecting which drugs should be made available to the population. As an example, consider the following: use of health in one culture, such as self-sufficiency, might be less significant than another facet of health care in another culture, such as living pain-free. As a result, when analyzing the generalizability of pharmacoeconomic assessments undertaken in other countries, caution must be exercised.[32]

FACTORSS AFFECTING PHARMACOECONOMICS

Several factors, including an increase in financial constraints and pressures on healthcare budgets, have led to an increased interest by policymakers in broadening pharmacists' role in care in recent years. These features include a patient-centered healthcare culture, quality-linked incentives, and patient-centered activities. Pharmaceutical services have been demonstrated in several studies to have positive therapy benefits in a wide spectrum of illnesses. However, proving the pharmacist's economic advantage in terms of decreasing overall healthcare spending, needless treatment, and societal expenses requires well-conducted, trustworthy, and transparent economic assessments, which are restricted.[33]

The field of pharmacoeconomics is a subset of health economics concerned with considering all these factors of interventions to maximize outcomes for patients, health - care funders, and the community through data-driven decision-making. A health technology assessment (HTA) method that informs government attendees about just the clinical, cultural, and economic consequences of health technological development, dissemination, and use, including clinical pharmacy treatments – might help guide these decisions. Several changes have occurred around pharmacy practice during the last several decades, with pharmacists transitioning from primarily completing prescription dispensing operations to providing tailored specialized as members of the medical care teams. These advancements in pharmaceutical care, as well as the pharmaceutical professionals who provide them, are increasingly being acknowledged as a critical asset in the healthcare system for assuring safe and proper prescription usage.[34]

RELATION OF ADR TO PHARMACOECONOMICS

A total of 8,862 ADRs were collected, resulting in a prevalence’s of 3.5 in 1,000 visits. % Of all ADRs could have been avoided, 46.4% were extreme, 15% needed inpatient, and 1.5 % caused death. The

Most prevalent organ related to ADRs was skins, gastrointestinal, respiratory system, and cardiovascular systems, and nervous system disorders. The number of simultaneously ingested drugs, age, yellow and red triage, and previous ED visits for a certain ADR were also documented. Hospitalization is highly connected with an increased risk and ADR management cost a total of €5,184,270, with an average price of €585 per participant. It was concluded that 58% of the financial impact could probably/certainly be avoided. In EDs, ADRs are a serious health and financial problems. This study examines the severity, prevention, and treatment, and burden impact of these diseases on a more populous in Europe. The median cost of ADR is €585 per patient. The economic cost was evaluated as possibly/certainly preventable 58% of the time. In EDs, ADRs are serious health and financial problem. This study examines the severity, avoidable, and financial effect on more populous originating inside typical Europe.[35]

We created a 22 table incorporating drugs with ADRs. That estimates the statistical association of medicines on ADR after determining of the ratio between ADRs and medications. Using the data, the ratios for every drug–ADR were determined. WHO-ART SOC assessed the pair using all ARRN codes. Signal requirements were a ROR more than 2 and a lower 95 percent confidence interval (LCI) greater than 1. OracleSQL and R were used to mine data and do statistical analysis.[36]

ADR AND PHARMACOECONOMIC BURDEN AFFECTING PATIENTS ESPECIALLY IN SURGICAL DEPARTMENT

ADRs place a significant strain on the NHS, resulting in significant morbidity, death, and additional expenses. Even though many of the medications implicated having have demonstrated benefit, steps must be taken to reduce the burden of ADRs and, as a result, improve the medicine's benefit-to-harm ratio.[37]

The high cost of medications continues to emphasize the rising importance of pharmacoeconomic evaluation research. These studies allow us to learn about, measure, & evaluate the overall costs of different pharmacotherapies and services. They'll have an influence on healthcare costs and patient care quality. Six patients affected by ADE had their hospitalization extended by an average of two days, at a cost of US$2,000–$2,500. Medication mistakes were costly for healthcare systems, but a high proportion of these are avoidable.[38]

ADRs were discovered in people over the age of 65 in a recent study by International Classification of Diseases (ICD), and With ADRs, the average hospitalisation cost per patient was predicted to be $1015. The average hospitalisation costs for people with cancer having chemo febrile neutropenia were $3964 on the cutting edge. The cost to the general public of rising ADRs is unclear.[39]

In Thailand, post- operative complication is a big problem since they are associated with an increased risk of death, duration of service, and health cost. Clinicians should create a technique to avoid or successfully manage postsurgical complications to decrease such expenses. Postsurgical complications are a significant clinical issue that imposes significant consequences on public health and the economy. A comprehensive university medical database analysis in the United States found that patients with one or more postsurgical problems had healthcare expenditures rising by 272 percent on average when compared to individuals who do not have difficulties.[40]

Older patients are more susceptible to medication-related disorders because they are often on several treatment regimens, putting them at risk for drug side effects, and because ageing is associated with changes in body kinetics and drug dynamics.[41]

Cost-benefit, cost-effectiveness, cost-minimization, and cost-utility research were examples of pharmacoeconomic techniques that can assist allocated reduced health resources (Reeder, 1995).

These studies give crucial information that was required to reduce the expenses associated with medication usage products. Notably, inappropriately dosed medication treatment can result in considerable avoidable medical costs and symbolizes a region that need work accurate dosing goals. Although accuracy dosage was recommended and had various benefits, despite its potential, it was underused in many medications and disease situations.[42]

STEPSS TAKEN TO REDUCE THIS BURDEN NATIONALLY AND GLOBALLY

By enhancing the allocative efficiency of health care finance, economic assessments assists to ease the burden of finite resources. In an increasing number of nations, reimbursement for new drugs was conditional on their cost-effectiveness and affordability. There were three primary methods for determining the cost-effectiveness of novel medications. Along with economic analyses due to insufficient economic data collection and protocol-driven expenses, pivotal clinical studies are frequently inconclusive. The selection bias was a key drawback of observational naturalistic economic assessments, as was the fact that they can only be undertaken once after registration and reimbursement.[43]



Fig 2 Level of evidence for pharmacoeconomic decision making [44]

Furthermore, policy transmission must occur. Take cultural conventions into consideration. As a result, in many nations, attempts to reduce hypertension in Asia must consider Indian traditional belief systems, for example, China and Southeast Asia, where "dis-ease" was synonymous with pain and illness, and there was little awareness of the significance of addressing an asymptomatic risk factor. In nations where even a little fee may be charged, it must also consider the affordability of both therapy and the means of receiving it (such as transportation fees) expensive for families that were already caught in a cycle of poverty debt.[45]

As a result, suggestions for pharmacoeconomic assessment were an important tool for ensuring a transparent and consistent procedure. When assessing the clinical benefit and costs of medications that don't work, rely on low acquisition costs as the fundamental foundation for decision-making and selection. These suggestions will aid in health-care decision-making judgments on how to improve health-care systems and achieve better outcomes Egyptians' health is a priority.[46]

Health interventions were subjected to cost-effectiveness analysis to assess and compare their effects on both duration and quality of life. Within this context, Quality-Adjusted Life Years and Disability-Adjusted Life Years are words are often used. Years spent in excellent health that were gained are referred to as QALYs, whereas yrs. Spent in great health that were lost are referred to as DALYs. In risk-benefit analysis, they're the most employed measures.[47]

EDUCATING PEOPLES ABOUT REPORTING OF ADR

This might be done on deliberately to expose additional patients or customers to the same drugs. ADR reporting in a hurry is both rational and questionable. Most effective methods for monitoring medication safety. ADR reporting and PV had substantial public health consequences since they help to avoid future incidents. Comparable ADRs, potentially saving lives and lowering costs the financial strain.[48]

It may be inferred, based on the study's findings, that patient awareness of reporting adverse reactions was poor. Patients were ignorant of the seriousness of adverse responses and the need of knowledge about negative responses. Patients were given conflicting advice on how to respond in the case of an emergency with negative response. As a result, knowledge must be expanded, or else ignorance will spread. To improve medication safety, it was necessary to emphasize the critical importance of adverse reaction reporting for public safety and to provide clear and simple protocols for reporting ADRs. The sufferers' Health-care providers and personnel must be educated. Department of Medicinal Adverse Reactions Monitoring Products at the Office for Medicinal Product Registration, with concerns relating to medical devices and biocidal products Patients' participation in research may be aided if ADRs were reported. The procedure for filing ADRs must be known to public relations initiatives which appear to be successful to play a critical part in the reporting of ADRs.[49]

The findings of this analysis show that an educational intervention can help physicians become more aware of ADRs. Physicians who took part in the study were able to use what they learned in face-to-face training in their everyday clinical practice. Nonetheless, the intervention's effects were just transitory. Larger study is needed to see if longer or ongoing educational interventions can result in more long-term gains in ADR reporting rates in everyday practice. This was especially significant given the rising popularity of complementary and alternative medicine.[50]

Only spontaneous reporting by healthcare professionals can ensure pharmacovigilance's survival, which was dependent on their understanding of pharmacovigilance as well as their willingness to report it. Their readiness to provide information because of our research, we've concluded that increasing healthcare practitioners' awareness and promoting ADR reporting were a need these days. Creating consistent schedule, between workshops and ongoing medical education will help to improve the situation. The degree to which healthcare professionals were aware of PV and other ways of promoting ADR must be devised. In our nation, there was a reporting culture.[51]

Many medical students started practice after graduating and they expected to regularly prescribing, distribution, deliver, and keeping an eye on drugs. Healthcare students need a master a minimum set of abilities to complete these duties quickly. Before they graduate and begin their careers in pharmacovigilance, clinical practice predicting, detecting, controlling, and resolving problems. ADRs are a curial part of the drug development process. Prescriptions were sensible and safe, and they were incorporated into many processes of the WHO's six-step Guide to Good Prescription Practices. All healthcare providers have a professional duty to do so.[52]

The average rate of underreporting in 37 studies from 12 nations. There was a 94 percent response rate (interquartile range 82-98 percent). The most critical reasons that contribute to the misreporting

of ADR have been identified. According to the programme, there is a lack of pharmacovigilance, competence, and awareness, as well as an insufficient risk perception of newly marketed drugs. Drugs, fear factor, and a lack of health care training programmes pharmacovigilance providers, job overload.[53]

PRESCRIPTION PATTERN ANALYSIS IN SURGERY DEPARTMENT

The purpose of this research was to determine the prescription trend at a tribal district hospital's surgical department to identify the amount of rational medicine usage. Most of the patients, 18 of them, were between the ages of 21 and 40. (36 percent). The most prevalent reason for hospitalization was renal calculi, following with acute abdomen and abscess. In all, 255 medicines were utilized, with a mean of 5.1 medications per patient. The most prevalent approach was intravenous. Antimicrobials, analgesics, and antipyretics were the most often given drugs. The most given antibiotic was ciprofloxacin, which was followed by metronidazole. Empirical therapy was used to address all patients. In 20 of the instances, two separate antimicrobials were administered. In 83 of the cases, the dosage was incorrect, while in 26 of the cases, the frequency was incorrect. To remedy certain unreasonable methods, immediate efforts such as specific instructions, training, and drug monitoring are required.[54]

In the bulk of these research, it was discovered that physicians do not follow regulatory agency requirements, resulting in illogical medication usage. This, in turn, leads to a higher rate of treatment failure. Antibiotic resistance and the financial cost to the patient and the community diseases are treated using the necessary medications that are given under their generic names. The WHO and India's National Health Policy have both underlined this.[55]

Drug prescription that is irrational is common all around the world. Prescription trends can be assessed using drug usage. Research was to determine on-going prescription pattern in hospital surgical wards. The most common reasons for admission were appendicitis (14.9%) and hernia (10.6%). The average length of stay was 7.44 days. A prescription had an average of 8.94 medications in it. Antibiotics (32.77%), analgesics (17.11%), and antacids (16.09%) were the most prescribed medication classes. Amikacin (5.81%) was the most regularly prescribed antimicrobial medicine, followed by metronidazole (5.30%) and ciprofloxacin (5.19%). Tramadol (5.31%) and pantoprazole (7.17%) were the most often prescribed analgesic and antacid medicines, respectively. At least one injectable medicine was included in every prescription. In 92.05 percent of prescriptions, at least one antibiotic was present. Generic names were prescribed for most medications (87.27 percent). The percentage of pharmaceuticals prescribed from the list of necessary medicines was 84.22 percent. Polypharmacy and the prescription of injectable drugs were also typical blunders. There is room for practitioners to improve their prescription procedures. When feasible, numerous antibiotics should be avoided, and their use should be evidence-based.[56]

CONCLUSION

Adverse medication responses account for a high number of out-patient hospital admissions as well as extended hospital stays, the majority of which are preventable. Nonetheless, the methodologies utilised to measure these avoidable costs are so different that understanding the true economic effect of ADRs that are avoidable. In this study, we emphasised how difficult it is to make the right judgments in order to reduce the societal costs of ADRs. Some expenditures may be estimated, but the entire cost of ADRs is extremely difficult to detect, measure, and calculate. It also implies that training on PV and ADRs has a good influence on nurses' knowledge and attitude.s The hospital's pharmacists are based on a social position of learning, involving the participation of all professionals. The patient’s involvement will enable for the implementation of cooperative best practises for reporting ADR. This study suggests that PPMS is useless in developing RUM in India, and drastic

actions need be made to correct it. In India, it is critical to utilise the data generated by the numerous PPMSs conducted in each state and on each medicine in order to achieve the primary goal of encouraging rational drug use.

Conflicts of Interest
There is no conflict of interest

Funding Statement

No source of funding received

Acknowledgments
I want to acknowledge to Piyush Mittal for the support and guidance.

References
1) Formica D, Sultana J, Cutroneo PM, Lucchesi S, Angelica R, Crisafulli S, Ingrasciotta Y, Salvo F, Spina E, Trifirò G. The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Expert Opin Drug Saf. (2018);vol-17(7);pg-681-695.
2) Thürmann PA. Methods and systems to detect adverse drug reactions in hospitals. Drug Saf. (2001);vol-24(13);pg-961-968.
3) Rajakannan T, Mallayasamy S, Guddattu V, Kamath A, Vilakkthala R, Rao PG, Bairy LK. Cost of adverse drug reactions in a South Indian tertiary care teaching hospital. J Clin Pharmacol. (2012); vol-52(4);pg-559-565.
4) Paluzzi RG. Antimicrobial prophylaxis for surgery. Med Clin North Am. (1993);vol-77(2);pg-427-41.
5) Thiesen S, Conroy EJ, Bellis JR, Bracken LE, Mannix HL, Bird KA, Duncan JC, Cresswell L, Kirkham JJ, Peak M, Williamson PR, Nunn AJ, Turner MA, Pirmohamed M, Smyth RL. Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children - a prospective observational cohort study of 6,601 admissions. BMC Med. (2013) vol-11:237.
6) Yadav d, Acharya R P. Incidence and severity associated with adverse drug reaction in surgery inpatients. J. Pharm. Sci. & Res. (2015); Vol- 7(9); pg-671-675
7) Ahmad A, Patel I, Parimilakrishnan S, Mohanta GP, Chung H, Chang J. The role of pharmacoeconomics in current Indian healthcare system. J Res Pharm Pract. (2013); vol-2(1); pg-3-9.
8) WilsonJ.P,RascatiK.L,Pharmacoeconomics,June18(2016):https://basicmedicalkey.com/pharmacoeconomics2/#:~:text=Pharmacoeconomic%20studies%20categorize%20costs%20into,medical%2C%20in direct%2C%20and%20intangible.
9) Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. (2013); vol-4; pg-S73-S77.
10) Lundkvist J, Jönsson B. Pharmacoeconomics of adverse drug reactions. Fundam Clin Pharmacol. (2004); vol-18(3); pg-275-280.
11) Rodrigues G S, Khan S A. Pharmacovigilance among surgeons and in surgical wards: overlooked or axiomatic. Indian J Surg. (2011); vol-73(1); pg-4-8.
12) Petrova G, Stoimenova A, Dimitrova M, Kamusheva M, Petrova D, Georgiev O. Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy. SAGE Open Med. (2017); vol-5; pg-1-8.
13) Hadi MA, Neoh CF, Zin RM, Elrggal ME, Cheema E. Pharmacovigilance: pharmacists' perspective on spontaneous adverse drug reaction reporting. Integrated Pharmacy Res Pract. 2017; 6:91–8.

14) Aagaard L, Strandell J, Melskens L, Petersen PS, Hansen EH. Global patterns of adverse drug reactions over a decade. Drug Safety. 2012;35(12):1171-82.
15) Chan S L, Ang X, Sani L L. Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. Br J Clin Pharmacol. (2016); vol-82(6); pg-1636-1646.
16) Hagos L, Fessehaye S, Anand I.S. Nature, and prevalence of adverse drug reaction of antiretroviral medications in Halibet National Referral Hospital: a retrospective study. BMC Pharmacol Toxicol (2019); pg-20-24.
17) Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med (Lond). 2016 Oct;16(5):481-485. doi: 10.7861/clinmedicine.16-5-481.
18) Abdullahi Rabiu Abubakar, Nordin Bin Simbak, Mainul Haque. Adverse Drug Reactions: Predisposing Factors, Modern Classifications and Causality Assessment. Research J. Pharm. and Tech. 7(9): Sept. 2014 Page 1091-1098.
19) Kumar A.P., Bhoopathi D., et al. An overview of various scales used in casualty assessment of adverse drug reactions. Int J Pharm Pharm Sci, Vol 12: pg-1-5.
20) Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharacol Ther. (1981); vol- 30:pg-239–245.
21) Srinivasan et al. Adverse Drug Reaction Casuality Assessment. IJRPC 2011, 1(3).
22) Shamim S, Sharib SM, Malhi SM, et al. Adverse drug reactions (ADRS) reporting: awareness and reasons of under-reporting among health care professionals, a challenge for pharmacists. Springerplus. (2016); vol-5(1):pg-1778-1882.
23) Giardina C, Cutroneo P.M, Mocciaro E, et al. Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study. Frontiers in Pharmacology, (2018). Vol- 9, pg-350–359.
24) Kim J., Ostroph A.D, tips for managing adverse drug reaction, jan 25(2017) https://www.pharmacytimes.com/view/tips-for-managing-adverse-drug-reactions
25) Edwards I.R. Adverse Drug Effects and Their Clinical Management: A Personal View. Drug Saf (2014); vol-37; pg-383–390.
26) Sheffer AL, Pennoyer DS. Management of adverse drug reactions. J Allergy Clin Immunol. (1984) vol-74; pg-580-588.
27) Wikipedia contributors. "Pharmacoeconomics." Wikipedia, The Free Encyclopedia. Wikipedia, The Free Encyclopedia, 28 Mar. 2022. Web. 27 May. 2022.
28) Rai M, Goyal R. Pharmacoeconomics in Healthcare., Pharmaceutical Medicine and Translational Clinical Research. pg-465–472.
29) Thomas D, Hiligsmann M, John D, Al Ahdab OG, Li H. Pharmacoeconomic Analyses and Modeling. InClinical Pharmacy Education, Practice and Research (2019); pg.- 261-275.
30) Miller P. Role of pharmacoeconomic analysis in R&D decision making: when, where how? Pharmacoeconomics. (2005); vol-23(1): pg. 1-12.
31) Wertheimer AI. The Importance of Pharmacoeconomics. Journal of Pharmacovigilance. Vol-2(1)115.
32) Owers K.M, Pharmacoeconomics is everyone's business. Journal of Pharmacy Practice and Research, (2016); vol-46(2); pg-192–192.
33) Tonin FS, Aznar-Lou I, Pontinha VM, Pontarolo R, Fernandez-Llimos F. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. Pharm Pract. (2021); vol-19(1):2302.
34) Qing-ping, S., Xiao-dong, J., Feng, D. et al. Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China. BMC Health Serv Res 14, 73 (2014).

35) Clementi, Emilio; Perrone, Valentina; Conti, Valentino; Venegoni, Mauro; Scotto, Stefania; Degli Esposti, Luca; Sangiorgi, Diego; Prestini, Lucia; Radice, Sonia; Vighi, Giuseppe Danilo. Seriousness, preventability, and burden impact of reported adverse drug reactions in Lombardy emergency departments: a retrospective 2-year characterization. ClinicoEconomics and Outcomes Research, (2014). Vol-(6); pg-505–514.
36) Hyunah S, Jaehun C, Youngho L, Jong y. k, Suehyun L. Real-world data-based adverse drug reactions detection from the Korea Adverse Event Reporting System databases with electronic health records-based detection algorithm. Health Informatics Journal. (2021); vol- 27(3).
37) Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. (2004); vol-329; pg-15-19.
38) Dalton K, Byrne S. Role of the pharmacist in reducing healthcare costs: current insights. Integr Pharm Res Pract. (2017); vol-6: pg37-46. Pudoi:10.2147/IPRP.S108047
39) Chan, S.L, Ng, H.Y, Sung C. et al. Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. Pharmacogenomics J. (2019); vol-19, pg-401–410.
40) Kongpakwattana k, Dilokthornsakul P, Dhippayom T, Chaiyakunapruk N,Clinical and economic burden of postsurgical complications of high-risk surgeries: A cohort study in Thailand. Journal of Medical Economics, (2020); vol-23(10); pg-1046-1052.
41) Onder G, Petrovic M, Tangiisuran B, et al. Development and Validation of a Score to Assess Risk of Adverse Drug Reactions Among In-Hospital Patients 65 Years or Older: The GerontoNet ADR Risk Score. Arch Intern Med. (2010);vol-170(13):pg-1142–1148.
42) Tyson R.J, Park C.C, Powell R.J, Patterson H.J, Weiner D Watkins P.B, Gonzalez D. Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables. Frontiers in Pharmacology, (2020) vol-11, 420.
43) Bodrogi J, Kaló Z. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br J Pharmacol. (2010); vol-159(7):pg-1367-1373.
44) Wöhrl S. Clinical work-up of adverse drug reactions. Expert Review of Dermatology, (2007);vol-2(2); pg-217–231.
45) Priyadi A., Permana H., Muhtadi A., Sumiwi, S.A., Sinuraya, R.K., Suwantika, A.A. Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia. Healthcare (basel). (2021), vol-9, 211.
46) McKee M, Haines A, Ebrahim S. et al. Towards a comprehensive global approach to prevention and control of NCDs. Global Health. (2014) vol-10, 74.
47) Elsisi, Gihan H.; Kaló, Zoltán; Eldessouki, Randa; Elmahdawy, Mahmoud D.; Saad, Amr; Ragab, Samah; Elshalakani, Amr M.; Abaza, Sherif (2013). Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt. Value in Health Regional Issues, 2(2), pg-319–327.
48) Measuring burden of disease: the concept of QALYs and DALYs dec 1(2011), https://www.eufic.org/en/understanding-science/article/measuring-burden-of-disease-the-concept-of-qalys-and-dalys
49) Shrestha S, Sharma S, Bhasima R, Kunwor P, Adhikari B, Sapkota B. Impact of an educational intervention on pharmacovigilance knowledge and attitudes among health professionals in a Nepal cancer hospital. BMC Med Educ. (2020); vol-20(1):179.
50) Staniszewska A, Dąbrowska-Bender M, Olejniczak D, Duda-Zalewska A, Bujalska-Zadrożny M. Patient knowledge on reporting adverse drug reactions in Poland. Patient Prefer Adherence. (2016); vol-11:pg-47-53.
51) Tabali, M., Jeschke, E., Bockelbrink, A. et al. educational intervention to improve physician reporting of adverse drug reactions (ADRs) in a primary care setting in complementary and alternative medicine. BMC Public Health (2009); 9, 274.

52) Bisht M, Singh S, Dhasmana D. C., Effect of Educational Intervention on Adverse Drug Reporting by Physicians: A Cross-Sectional Study, International Scholarly Research Notices. (2014), volume 2014 pages 8.
53) Reumerman, M., Tichelaar, J., Piersma, B. et al. Urgent need to modernize pharmacovigilance education in healthcare curricula: review of the literature. Eur J Clin Pharmacol. (2018); vol-74, pg-1235–1248.
54) Vo TH, Dang TN, Nguyen TT, Nguyen DT. An Educational Intervention to Improve Adverse Drug Reaction Reporting: An Observational Study in A Tertiary Hospital in Vietnam. Arch Pharma Pract (2020); vol-11(3):pg-32-37.
55) Khade A, Bashir M, Sheethal A. Prescription pattern in the department of surgery in a tribal district hospital of andhra pradesh, India. Ann Med Health Sci Res. (2013); vol-3(3):pg-438-441.
56) Jain S, Upadhyaya P, Goyal J, et al. A systematic review of prescription pattern monitoring studies and their effectiveness in promoting rational use of medicines. Perspect Clin Res. (2015); vol-6(2):86-90.